Drug Trial Radar · NCT07637513
Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
430
Planned (sponsor's estimate)
Start
Jan 2027
Primary completion
Nov 2037
Study completion Jun 2038
Sponsor
- Lead sponsor
- PrECOG, LLC.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Amgen
- First posted
- Jun 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Eligible participants with limited stage-small cell lung cancer (LS-SCLC) will be enrolled after completion of chemotherapy and radiation. Participants will be randomized to either tarlatamab in combination with durvalumab or durvalumab alone as consolidation therapy. Treatment will continue until disease progression, unacceptable side effects or withdrawal of consent. Tarlatamab is a targeted cancer treatment. It works by acting as a matchmaker between the immune system's T-cells and the cancer cells, forcing them to come together so the T-cells can attack the cancer. Image testing will be done standardly during treatment. These tests show whether the cancer has progressed and if further treatment may be needed. The purpose of this trial is to evaluate how well the treatment works (how long before your cancer comes back and how long you live).
Conditions
- Limited Stage Small-Cell Lung Cancer
Interventions
TarlatamabDrug
Tarlatamab Intravenous (IV): Cycle 1 Step Dose: Day 1- 1 mg; Day 8- 10 mg; Day 15- 10 mg of a 28-day cycle, then Cycle 2 and Subsequent Cycles: Day 1- 10 mg and Day 15- 10 mg every 28-day cycle up to 12 months from cycle 1 day 1 unless other treatment discontinuation or rechallenge criteria are met.
DurvalumabDrug
Durvalumab 1500 mg IV: Every 4 weeks until disease progression, unacceptable toxicity, or a maximum of 24 months from cycle 1 day 1, unless other treatment discontinuation criteria are met.
Primary outcomes
What the sponsor says the trial is designed to measure.
- This phase III study has dual primary endpoints of progression-free survival (PFS) and overall survival (OS).Time frame: From randomization until death due to any cause, assessed up to 131 months.
- This phase III study has dual primary endpoints of progression-free survival (PFS) and overall survival (OS).Time frame: From randomization until the first documentation of radiologic disease progression or death due to any cause, whichever occurs first, assessed up to 131 months.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.